30
Participants
Start Date
November 30, 2023
Primary Completion Date
November 30, 2028
Study Completion Date
November 30, 2028
Relma-cel Followed by Tislelizumab
Enrolled patients with relapsed/refractory (R/R) CNSL will receive Relma-cel infusion, followed by treatment with Tislelizumab (200mg, IV, q4w, for 12 months) starting at 35 days post-infusion. BTK inhibitors will be used in combination as needed.
NOT_YET_RECRUITING
Beljing Tiantan Hospital, Capttal Medical, University, Beijing
NOT_YET_RECRUITING
Xuanwu Hospital Capital Medical University, Beijing
NOT_YET_RECRUITING
Sun Yat-Sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Henan Cancer Hospital, Henan
RECRUITING
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
NOT_YET_RECRUITING
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,, Wuhan
Ruijin Hospital
OTHER